GLP-1 Drugs May Reduce Alcohol Use Disorder Risk After Bariatric Surgery | Research

The takeaway

Analysis found that GLP-1 receptor agonist use was associated with improved alcohol use disorder outcomes in patients after Roux-en-Y gastric bypass surgery.

Addiction risk reduced
GLP-1 drugs associated with improved alcohol use disorder outcomes after gastric bypass surgery

What the researchers found

GLP-1 receptor agonist use was associated with improved alcohol use disorder outcomes in post-Roux-en-Y gastric bypass patients.

Why it matters

Post-bariatric alcohol addiction is a serious and underrecognized problem. If GLP-1 drugs reduce this risk through brain reward pathway modulation, they could address both weight and addiction in post-surgical patients.

The numbers in context

Adults ≥18 years with BMI ≥30 who had RYGB between January 2019 and May 2023. Two cohorts compared: GLP-1 RA initiators vs. non-initiators post-surgery.

How the study worked

Retrospective analysis of AUD outcomes in post-RYGB patients comparing GLP-1 RA users vs non-users.

Who was studied

Adults with BMI ≥30 who underwent RYGB (2019-2023), comparing GLP-1 RA users to non-users

What this study cannot tell us

Retrospective study with potential confounders. Patients on GLP-1 drugs may differ in other ways from non-users. AUD is complex and multifactorial.

How to read the evidence

Preliminary evidence: retrospective association study. Prospective trials needed to confirm anti-addiction effects.

When this study was published

Published in 2025. Adds to emerging evidence for GLP-1 drugs in addiction medicine.

The bigger picture

GLP-1 drugs are being studied for multiple addictions — alcohol, nicotine, opioids. Brain GLP-1 receptors modulate the dopamine reward system that drives addictive behavior. This study adds post-surgical alcohol addiction to the growing list of conditions where GLP-1 drugs show benefit.

Questions still open

Should GLP-1 drugs be preferentially prescribed to post-bariatric patients at AUD risk?
Do GLP-1 drugs reduce alcohol consumption through brain reward modulation or other mechanisms?
Could GLP-1 drugs be developed as AUD treatments independent of weight management?

Common questions

Can GLP-1 drugs help with alcohol addiction?

Emerging evidence suggests GLP-1 drugs reduce addictive behaviors by affecting brain reward circuits. This study found improved alcohol outcomes in post-bariatric patients on GLP-1 drugs. While not yet an approved addiction treatment, clinical trials are investigating this application.

Why do people develop alcohol problems after bariatric surgery?

After gastric bypass, alcohol is absorbed faster and metabolized differently, leading to stronger intoxication from less alcohol. Changes in brain reward signaling after surgery may also increase addiction vulnerability. GLP-1 drugs may counteract these changes.

Read the original research

Alcoholic Use Disorder Outcomes After Roux-en-Y Gastric Bypass in Patients Taking GLP-1 RAs: A Multicenter Analysis.

Obesity (Silver Spring, Md.), 33(10), 1886-1894

View on PubMed ↗Publisher’s paper ↗

Citation

Adeniran, Olanrewaju; Nieto, Luis M; Amadi, Chima; Shepherd, Katherine; Kirkpatrick, Joshua; Farah, Kanith; Marwizi, Farirai; Alqinai, Budoor; Narvaez, Sharon I; Mensah, Samuel; Adekolu, Ayowumi; Cohen, Ethan M; Khan, Raja S; Gayam, Swapna; Tabone, Lawrence E; Davisson, Laura. (2025). Alcoholic Use Disorder Outcomes After Roux-en-Y Gastric Bypass in Patients Taking GLP-1 RAs: A Multicenter Analysis.. Obesity (Silver Spring, Md.), 33(10), 1886-1894. https://doi.org/10.1002/oby.70001